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Background: Several uncertainties remain concerning the management of intramedullary spinal cord tumours
(IMSCTs). These include the timing and extent of resection, its interrelated functional outcome, and the adequate
use and timing of radiation therapy and/or chemotherapy. In this retrospective study we report on all adult cases
involving IMSCTs treated from 1987 to 2007 in our institution to validate our treatment strategy for IMSCTs.
Pre- and post-operative functional performance was classified according to the McCormick scale.
Results: A total of 70 adult cases with IMSCTs consisting of ependymoma (39), astrocytoma (11), carcinoma
metastasis (8), haemangioblastoma (5), cavernoma (3) and others (4) were reviewed. Mean age was 46.8 years
(range, 18-79 years), and mean follow-up was 4.5 years (range, 1-195 months). The proportion of localisation in
descending order was thoracic (36%), cervical (33%), cervicothoracic (19%) and conus region (13%), with 45 gross
total resections, 22 partial resections and three biopsies. Surgery-related morbidity with worsening postoperative
symptoms occurred immediately in 13 patients (18.6%). The preoperative McCormick grade correlated significantly
with the early postoperative grade and the grade at follow-up (χ2-test; p = 0.001). None of the patients with
preserved intraoperative evoked potentials exhibited significant postoperative deterioration. The degree of resection
was correlated with progression-free survival (Duncan test; p = 0.05). Most patients with malignant tumours, namely
anaplastic ependymoma (3), astrocytoma (2) or metastatic lesions (5), underwent postoperative radiation therapy.
Six patients (one anaplastic ependymoma, two anaplastic astrocytomas and three metastatic lesions) received
postoperative chemotherapy.
Conclusions: IMSCTs should be operated on when symptoms are mild. We recommend evoked potential-guided
microsurgical total resection of ependymomas and other benign lesions; partial resection or biopsy followed by
adjuvant therapy should be confined to patients with high-grade astrocytomas, whereas resection or biopsy with
adjuvant therapy is the best option for metastatic lesions.
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Intramedullary spinal cord tumours (IMSCT) are rare le-
sions and constitute only 4-10% of all primary central
nervous system tumours [1,2]. IMSCTs are less common
in adults than in children and constitute 20% and 35%,
respectively of all intraspinal tumours [1-4]. The most
commonly occurring intramedullary neoplasm is spinal
ependymoma followed by glioma and other lesions [2,5-7].* Correspondence: Jan.Bostroem@ukb.uni-bonn.de
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unless otherwise stated.Treatment strategies in IMSCT have been reported in the
past by numerous authors; in the last decade, there seems
to have been a general agreement that these lesions need
early resection, and whenever feasible complete resection,
to achieve a good functional outcome [2,4,8].
Nowadays, the microsurgical technique, including the
use of an ultrasonic aspirator (Cavitron Ultrasonic Surgical
Aspirator [CUSA]), is employed as standard. Many studies
have recommended the routine use of electrophysio-
logical monitoring, mostly somatosensory-evoked po-
tentials (SSEP), although in some cases motor-evoked
potentials (MEP) are also used; however, only a few studiesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ports, the study period dates back to the non-microsurgical
and non-magnetic resonance imaging (MRI) era, providing
the opportunity to evaluate a long mean follow-up period
and a resultant increase in the statistical power. However,
this makes it impossible to exclude biases from changes in
the treatment strategy, diagnostic imaging technologies
and surgical techniques in the long-term. The number of
reported cases ranges between 34 and 202 [2-4,8].
The purpose of the present study was to retrospect-
ively review the results regarding the surgical treatment
of IMSCT at our hospital during the last 20 years, to elu-
cidate the problems associated with surgery and to valid-
ate the treatment strategy for these tumours.
Methods
All adult patients who underwent surgical therapy for an
IMSCT at our institution between 1987 and 2007 were
reviewed for this study; only children with an IMSCT
were not included. Patient charts, and surgical and histo-
logical reports were analysed. In those patients with no
follow-up data in the charts, a standardised telephone
interview was performed. Two patients were not avail-
able for a telephone interview.
Standard therapy consisted of a complete resection
involving a microsurgical technique using CUSA when-
ever feasible. Tumours were operated on using standard
dorsal approaches as indicated by the location of the
lesions (classification of the location: C0-C7 = cervical,
TH1-12 = thoracic and L1-5(6) = lumbar with conus; tu-
mours involving cervical segment(s) and thoracic seg-
ment(s) were classified as cervicothoracic and tumours
involving thoracic and lumbar segments were classified
as thoraco-lumbar). Regularly, it was a laminectomy that
was performed. Only the multi-level cases underwent
surgery using laminoplasty. There was no case involving
primary dorsal fusion. A sitting position was favoured if
the tumour was localised in the upper cervical region,
and a prone position was favoured if the tumour was
localised in the lower cervical, thoracic or lumbar spine.
After midline dural incision over the dorsal surface of the
spinal cord, followed by lateral dural sutures, a midline
myelotomy was carried out and used as a natural plane
of dissection to avoid injury to the axonal tracts.
Recognition of the accurate position of the midline
prior to myelotomy is essential in minimising neuro-
logical defects. We relied on the identification of the
posterior spinal arteries in the healthy spinal cord, lo-
cated proximally and distally to the tumour, to estimate
the myelotomy incision site.
In our hospital, intraoperative monitoring was imple-
mented early in 1989; hence, this technology was avail-
able for 18 out of the 20 years of the study period. In all
cases, the tumour was obtained for histopathologicalexamination and classified according to the World Health
Organisation (WHO) classification at the same institution
whenever feasible (Reference Centre for Brain Tumours).
Each patient’s neurological status was recorded using
the McCormick classification scheme (i.e. ranging from
Grade I [neurologically intact] to Grade IV [severe func-
tional disability]) [5].
Statistical analysis
Tumour extension and localisation, preoperative neuro-
logical status, WHO grade and electrophysiological results
were correlated with neurological outcome postopera-
tively and at follow-up. Progression-free survival (PFS)
was estimated using the Kaplan-Meier technique. The
χ2-test for independence, and univariate and multivariate
analysis were employed for statistical evaluation using
Excel (Microsoft, Seattle, WA, USA) and SPSS (SPSS Inc.,
Chicago, IL, USA) software.
Pertinent clinical data and follow-up information were
collected by means of chart review and telephone inter-
views, as required. The clinical data were collected after
informed consent to conduct the telephone interviews.
Consent to publish was obtained from patients in ac-
cordance with the tenets of the declaration of Helsinki,
and after approval of the study by the Ethics Committee
of the Medical Faculty of the University of Bonn.
Results
A total of 70 adult patients (37 men and 33 women)
underwent primary surgical therapy for IMSCT at our in-
stitution; five children with IMSCT were excluded from in
this study. The patients ranged in age from 18 to 79 years
(mean 46.8 years) with a median follow-up of 55 (range,
1-195) months. Only one patient with an ependymoma
had undergone a previous resection. Histological diag-
nosis revealed ependymoma (n = 39; including one sube-
pendymoma), 11 glial tumours (pilocytic astrocytoma
WHO Grade I [n = 5]; glioma WHO Grade II [n = 3];
pleomorphic xanthoastrocytoma [n = 1]; anaplastic astro-
cytoma WHO Grade III [n = 3]), carcinoma metastasis
(n = 8), haemangioblastoma (n = 5), cavernoma (n = 3),
arteriovenous malformation (AVM; n = 2) and other histo-
logical diagnoses [n = 2]) (Figure 1). The most frequently
involved localisation was in the thoracic region (36%),
followed by the cervical region (33%), the cervicothoracic
region (19%) and the thoraco-lumbar (with conus) region
(13%) (Figure 2). One case demonstrated holospinal in-
volvement. We performed 45 gross total resections, 22 par-
tial resections and three biopsies.
Preoperative SSEP/MEP monitoring was performed in
41 cases (58%) and intraoperative monitoring in 24 cases
(35%; among them there were 16 SSEP and/or 19 MEP
investigations). Postoperative SSEP/MEP monitoring for















Figure 1 Histology of intramedullary tumours. Incidence of histologies of intramedullary tumours over a 20 year period (1987-2007).
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The results concerning the McCormick graduation pre-
and post-operatively (before discharge) and at last
follow-up are presented in Figure 3 and Tables 1 and 2.
No surgery-related mortality was encountered. An imme-
diate improvement after surgery was achieved in five
(7.1%) patients. Surgery-related morbidity with a worsen-
ing of symptoms immediately after the surgical proced-
ure occurred in 13 (18.6%) patients. In three patients, the
McCormick grade improved during follow-up to the
same grade as that prior to surgery. In total, the overall
surgery-related permanent morbidity was 14.3%. It is no-
ticeable that in 8/10 (80%) cases with permanent deteri-
oration, the resection was incomplete. Nearly all patients
with a high grade tumour (WHO Grade III ependymoma
or astrocytoma, and all metastatic lesions) were worse on
discharge or at last follow-up because of progression or
the presence of a recurrent tumour. Most patients with
benign or vascular lesions (cavernoma, AVM, haeman-
gioblastoma) remained stable post-operatively and at
follow-up (for details see section entitled Separate ana-
lysis of different pathologies).36%
19%
13%
Figure 2 Localisation of intramedullary tumours. Incidence of localisatiAdjuvant therapy
Subsequent adjuvant therapy, which consisted of radiation
therapy and/or chemotherapy, was only administered to pa-
tients with neuroepithelial WHO Grade III tumours (n = 5)
and in all but one patient with metastases including an
esthesioneuroblastoma metastasis (n = 7). For details see
section entitled Separate analysis of different pathologies.
Statistical analysis
Advancing age (>60 years) was not found to be a statisti-
cally relevant prognostic factor regarding PFS in our
series (p > 0.05). Age and gender had no significant effect
on the post-operative neurological outcome or on neuro-
logical outcome at follow-up (p > 0.05). In addition, the
WHO grade (if applicable) had no significant effect on the
neurological outcome at follow- up in our series (p > 0.05).
The degree of resection (biopsy vs. total resection) was
correlated with PFS (Duncan test, p = 0.014). It was also
found that pre-operative status (McCormick grade) was
significantly correlated with the early post-operative
grade and with the grade at follow-up (χ2-test, p = 0.001)





ons of intramedullary tumours over a 20 year period (1987-2007).
Figure 3 Neurological status. Development of neurological status according to the McCormick classification.
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Ependymoma (n = 39)
Total resection was achieved in 30 of the 39 cases of
ependymoma (79%). In the remaining cases, only sub-
total resection could be performed because the boundary
between the tumour and the spinal cord was indistinct
(n = 8), or the amplitude of the intraoperative spinal
evoked potential decreased frequently (n = 1).
Most tumours were WHO Grade II (n = 31); in one
case, a primary anaplastic ependymoma WHO Grade III
was diagnosed, while the first tumour recurrence in
another case was WHO Grade III. The remaining six
tumours were WHO grade I. Both anaplastic tumours
received radiation therapy. One patient with a WHO
Grade II ependymoma exhibited further recurrent tumour
at 4 years after, which was five levels below the initial
tumour localisation. In this case, a neoplastic meningiosis
was diagnosed and the patient underwent additional
chemotherapy consisting of the intrathecal application of
etoposid (VP16) and salvage chemotherapy with carbo-
platin, cyclophosphamide and vincristine.
Tumour recurrence after complete resection (n = 2) or
tumour progress after subtotal removal (n = 4) of the
ependymomas was encountered in 6/39 cases (15%). In
five patients, recurrence occurred at the former tumour
level, and at multiple levels in one patient. RecurrentTable 1 Neurological status according to McCormick
classification postoperatively significantly depending on





I II III IV
(n = 11) (n = 35) (n = 15) (n = 9)
I 7 (63,6%) 2 (5,7%) 0 0
II 3 (27,3%) 26 (74,3%) 2 (13,3%) 0
III 1 (9,1%) 5 (14,3%) 11 (73,3%) 1 (11,1%)
IV 0 2 (5,7%) 2 (13,3%) 8 (88,9%)tumours of WHO Grade I were diagnosed between 36
and 59 months (mean 46 months) after treatment; inter-
estingly, all were ependymoma of the myxopapillary sub-
type. In patients with WHO Grade II tumours, the
recurrences occurred between 5 and 24 months (mean
14 months) after the first operation. In four cases, func-
tional improvement was obtained after complete resec-
tion. Deterioration was observed post-operatively in
eight patients. In three cases, there was a subtotal resec-
tion (3 of 9 incomplete resections = 33%). Deterioration
was observed in only five of the 30 completely resected
tumours (17%).
A not significant but potential prognostic factor re-
garding ependymomas appears to be tumour localisa-
tion. An investigation concerning the impact of the level
of tumour localisation on treatment outcome revealed
that in five out of 20 patients (25%) with thoracic in-
volvement, the outcome was worse than was the case for
cervical or conus/lumbar localised tumours (15% [2/13]
and 17% [1/6], respectively). Improvement was observed
in one of the cervical and one of the cases with conus
involvement, whereas only three of the thoracic cases
showed improvement.
In summary, the prognosis of ependymomas appears
to be favourable, with 36 patients (89.5%) still alive and
in good condition at the last follow-up. The functionalTable 2 Neurological status according to McCormick
classification at follow-up significantly depending on the





I II III IV
(n = 11) (n = 34) (n = 15) (n = 8)
I 7 (63,6%) 7 (20,6%) 0 0
II 3 (27,3%) 16 (47,1%) 3 (20,0%) 0
III 1 (9,1%) 8 (23,5 %) 6 (40,0%) 2 (25,0%)
IV 0 3 (8,8%) 3 (20,0%) 6 (75,0%)
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paralysis was mild.
Glioma (n = 11)
Total resection was achieved in only one of eight cases
of low grade glioma, and a subtotal resection (>90%) was
achieved in another case. A partial resection was per-
formed in four patients because the boundary between
the tumour and the spinal cord was indistinct. Biopsy
alone was performed in the remaining two patients, be-
cause of the location and multilevel extension in one
cervical (four levels) and one cervicothoracic (15 levels)
case. However, in the high-grade group, no total resection
or subtotal resection was performed; here only partial re-
section (two cases) or biopsy (one case) was performed.
One incompletely resected WHO Grade I astrocytoma
recurred at 3 years after treatment as a Grade III
tumour, and the patient received both radiation therapy
and chemotherapy consisting of nimustine (ACNU). Both
patients with WHO Grade III primary anaplastic astrocy-
tomas received chemotherapy consisting of procarbacin,
carmustin and vincristine (standard PCV scheme).
The functional outcomes were poorer in the astrocy-
toma than in the ependymoma cases; post-operative im-
provement of paralysis was found only in one patient at
last follow-up. Nine of 11 patients (82%) were neuro-
logically stable and two patients were worse; one had a
thoracic low-grade tumour which was spreading over 10
levels with partial resection and one was found to have a
cervicothoracic high-grade glioma after biopsy. Of the
11 glioma patients, three patients in the low grade group
had died at the time of the final survey, but there were
two 5-year survivors in the high grade group. Because of
the small number of cases, assessment of the impact of
the differences in the surgical procedures and the impact
of the level of the tumour localisation on the prognosis
did not reveal any statistical significance.
Metastatic lesions (n = 8)
Total resection was possible in 50% of the cases. Adju-
vant therapy in the form of radiation therapy was ad-
ministered to five out of the eight patients (total dose,
30–40 Gray [Gy]), two patients received additional chemo-
therapy and one patient received palliative chemotherapy
alone. One patient died before the planned adjuvant
therapy. In addition, five of the eight cases arose from
primary lung cancer, with small cell carcinoma being
the most common subtype; one metastasis originated from
renal cell carcinoma (n = 1), one case was a filia of an
esthesioneuroblastoma, and there was one metastasis of a
cancer of unknown primary (CUP) with histologically
proven adenocarcinoma.
All five lung cancer patients died within 6 months
of treatment; the patient with renal cell carcinomaexperienced a symptom-free interval of 13 months, the
CUP patient had a follow-up period of 8 months and the
patient with the esthesioneuroblastoma was recurrence
free for 4 months. At post-operative evaluation, one pa-
tient had improved and one had deteriorated; all of the
other patients were functionally similar. At the last follow-
up, the three surviving patients demonstrated deterior-
ation caused by disease progression.
Haemangioblastoma (n = 5)
The strategy for the microsurgical removal of haeman-
gioblastoma was somewhat different from other IMSCTs.
Our strategy was to coagulate the dominant arterial
feeders at the entrance of the tumour (in most cases these
were identified by additional spinal angiography) by bipo-
lar coagulation involving low power first, followed by
coagulation and shrinkage of the tumour and lastly coagu-
lation of the venous drainage. Finally, the tumour was
carefully excised en bloc. Total resection was possible in
four of five patients; in the remaining patient only partial
resection could be performed because the intra-operative
spinal evoked potentials were lost. In this case and in one
other case, von Hippel-Lindau disease was diagnosed.
Only the one patient who underwent partial resection
showed a relevant neurological deficit pre- and post-
operatively; in all of the other patients, pre-operative par-
alysis was mild and their functional outcomes were even
better than those who had ependymomas, with one post-
operative improvement in one patient and a stable
condition in all of the other patients. The patient who
underwent an initial partial resection developed two recur-
rences together with further neurological deterioration.
Vascular lesions (n = 5)
Cavernomas and AVMs are very rare and extremely vari-
able (in terms of size, location and the vessels involved),
usually making the interpretation of surgical results case
sensitive. We treated three patients with cavernoma and
two patients with an AVM; all of these intramedullary
vascular lesions could be resected in toto. In two patients
with cervical cavernomas, a worsening from McCormick
Grade II to III at post-operative evaluation was noted;
both were stable at the last follow-up and a third case
with a medullo-cervical cavernoma demonstrated a late
deterioration at the last follow-up. In the AVM patients,
there was one worsening post-operative (conus) case
and one improvement at last follow-up (cervical AVM
with incomplete embolisation pre-operatively).
Other histological diagnoses (two cases)
One case was a 28 year old male patient who had a
thoracolumbar intramedullary dermoid cyst with associ-
ated spina bifida occulta at level L5/S1. At the imme-
diate post-operative evaluation, the patient remained
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operatively) the patient exhibited a significant neurological
deterioration (McCormick Grade IV), which was most
likely associated with a tethered cord. The other case, a 73
year-old female who had severe functional disabilities, was
a patient who had a spontaneous cervical haematoma
caused by marcumar therapy, without histological proof
of any tumour or vascular malformation before surgery,
and who did not show neurological improvement post-
operatively (McCormick Grade IV).
Discussion
The management of intramedullary spinal cord tumours
has been influenced by some drastic improvements in
treatment during the last decades. Advances in imaging
and surgical techniques have led to the removal of many
tumours with a high success rate and low morbidity
[2,10,13]. However, the relative rarity of these tumours
makes the accumulation of data from large patient series
difficult. In many situations, there is still an incomplete
knowledge base regarding the optimal management of
IMSCT. Some published series providing long-term
follow-up data have included paediatric patients or pa-
tients treated long before the advent of the microsurgical
and MRI-era [3,4,13,14]. The present report details func-
tional and oncological outcomes, together with elec-
trophysiological data from adult patients with IMSCT
operated on solely in the microsurgery and MRI-era from
1987–2007 at one single institution. Although we have ex-
clusively analysed adult cases in the microsurgical and
MRI-era, the number of patients (n = 70) enrolled in our
study and the mean follow-up period (55 months) are
comparable with former reports [3,8,15].
In a series of 202 cases involving long-term follow-up
of IMSCT, Raco et al. [4] found a number of potential
determinant predictors of a good outcome after surgery,
including histological type of lesion, complete removal
of the lesion and satisfactory neurological status before
surgery. These findings are in line with ours. However,
the WHO grade had no significant effect on the neuro-
logical outcome at follow-up in our series. Raco et al. [4]
presented a large case series, but included patients over
a longer period (1972– 2003) than was the case in our
study; therefore, many cases were treated well before the
MRI and microsurgery-era. We excluded all of those
cases to avoid any bias regarding changes in surgical and
diagnostic quality.
In 2005, Sandalcioglu et al. [8] reported their experi-
ence with 78 patients between 1990 and 2000. In their
series, the strongest predicting factor of functional out-
come was again the preoperative neurological condition,
beyond the histological differentiation of IMSCT. Al-
though there was no difference in therapeutic outcome
with respect to age and tumour extension, thoracic IMSCTwas found to harbour an increased risk of postoperative
surgical morbidity. In our series, higher morbidity was
associated with surgical removal of multilevel thoracic
lesions without reaching statistical significance. Thor-
acic tumours spanning several levels may require exten-
sive dissection and manipulation of the spinal cord to
expose the tumour, with an increased risk of postopera-
tive surgical morbidity.
In 2009, Matsuyama et al. [13] reported on 106 pa-
tients operated on between 1997 and 2007; the mean
follow-up period was 7.3 years. The age range was 6-75
years; therefore, in this series, infantile cases were in-
cluded. Because the natural history of most infantile
cases differs relative to the adult cases, we also excluded
infantile cases in our series. Again, the postoperative am-
bulatory ability was excellent in patients with a good
preoperative neurological status. Total excision in pa-
tients with good ambulation was associated with a good
prognosis for post-operative mobility. The rate of post-
operative deterioration was 31% [13], which was rela-
tively high compared with our series with a rate of early
post-operative deterioration of 18.6%. We can confirm
that individuals with mild-to-moderate deficits often
improve significantly following surgical removal of the
tumour, while those with advanced neurological com-
promise generally exhibit no worthwhile improvement.
In our opinion, this emphasises the need for early inter-
vention and close follow-up.
Some additional general conclusions can be drawn
from our data, in combination with the relevant litera-
ture. Although the value of total excision of ependymo-
mas is widely accepted [16-19], the value of radical
resection of astrocytomas is less certain. If an ill-defined
plane is present, the risk-to-benefit ratio for aggressive
removal is not clear. Currently, no satisfactory modality
is available for the treatment of non-resectable and ma-
lignant astrocytomas. Fortunately, anaplastic astrocytoma
or glioblastoma are rare. Surgical therapy alone does not
improve the usually dismal disease course; therefore, adju-
vant radiation therapy and/or chemotherapy are options
[6,14,20-26]. Data are available which suggest that surgi-
cally excised ependymomas do not need to undergo subse-
quent radiation therapy [16-19]. However, the optimal
management of residual or recurrent tumour has not been
determined. Whether or not repeat excision, watchful
waiting or radiation therapy is the best choice requires fur-
ther clarification [1,27].
Radiation therapy involving neuroepithelial tumours
may be useful for residual tumour after surgery and re-
current tumour, but controversy exists regarding this
treatment [18,28,29]. This modality may also be the pri-
mary treatment for inoperable tumours and aggressive
lesions such as anaplastic astrocytomas and glioblastomas;
however, currently no radio-oncologist should undertake
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have reported reduced local failure rates when a total ra-
diation dose of 50 Gy was administered [22,30]. Modern
techniques like image-guided radiotherapy or stereotac-
tic radiosurgery can ensure the delivery of a therapeut-
ically effective dose to the tumour while spearing the
healthy surrounding tissue; these techniques may have
a role to play in management in the future, in a similar
manner to their current role in the management of intra-
cranial tumours [31-33].
Chemotherapy is still considered experimental in the
treatment of adult spinal cord tumours; a number of
protocols are undergoing examination, primarily involv-
ing childhood astrocytomas [34-36]. We have used stand-
ard chemotherapy protocols for cerebral gliomas (PCV
and ACNU) for malignant neuroepithelial tumours in
our series. We can report two long-term survivors with
anaplastic astrocytoma after a follow-up time of >5 years
who are still alive, and have received radiation ther-
apy (total doses of 45 and 50.4 Gy) and chemotherapy
(ACNU and PCV).
Total removal of the neoplasm, with preservation of
neurologic function, is the goal in most cases. Monitor-
ing spinal cord function using intraoperative electro-
physiology modalities, such as SSEP and motor-evoked
potentials (MEP), may reassure the surgeon during the
procedure and perhaps lead to improved outcomes [12].
None of our patients with preserved intra-operative
MEP/SSEP exhibited immediate significant postoperative
deterioration. In our series, the fact that intraoperative
electrophysiology was used in only 35% of all cases, and
monitoring was not applicable in 12% of the cases be-
cause of technical problems, attracted our attention;
thus it is remarkable that our study outcome is compar-
able with those of other studies with the use of much
more extensive intraoperative monitoring [9,10,13].
Study limitations
Because this study involved a single centre, the data pre-
sented are not representative and the results cannot be
generalised. However, the study can still be of value
when viewed as a sample study submitted by a major
neurosurgery department. Vascular lesions are very rare
and extremely variable (in terms of size, location and
vessel involvement), usually making the interpretation of
surgical results case sensitive. Consequently, such rare
lesions should be further investigated in multi-centre
series.
Conclusions
Intramedullary ependymomas should be operated on when
symptoms are mild. Early surgery can achieve an excellent
outcome. We recommend evoked potential-guided aggres-
sive microsurgical resection of most ependymomas andother benign lesions, because these lesions regularly
showed excellent functional outcome and no tumour re-
currence. Partial resection or biopsy followed by radiation
therapy should be confined to patients with high-grade
astrocytomas. Biopsy or partial resection and adjuvant
therapy involving radiation therapy and/or chemotherapy,
depending on the primary tumour type and site, is the
preferred option regarding metastatic lesions.
Consent
Clinical data was collected after written informed con-
sent to publish details included within this research art-
icle was obtained from all of the patients in accordance
with the tenets of the declaration of Helsinki and after
approval by the Ethics Committee of the Medical Faculty
of the University of Bonn. An additional consent from
the next of kin of deceased patients here was not neces-
sary because each patient has signed his consent on ad-
mission to our hospital, that his data may be scientifically
evaluated and published.
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